SCHEMBL20539163

SCHEMBL20539163

COc1ccc(COCc2cccc(-c3cccc(CO)c3C)c2C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 6/20 0.46
▸ PDCD1 Q15116 3/20 0.46
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ FFAR1 O14842 2/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.40
▸ IDO1 P14902 2/20 0.39
▸ AGXT P21549 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ABCB1 P08183 2/20 0.38
▸ MAOB P27338 1/20 0.38
▸ TUBB4A P04350 1/20 0.37
▸ TUBB P07437 1/20 0.37
▸ TUBA3C P0DPH7 1/20 0.37
▸ TUBA1B P68363 1/20 0.37
▸ TUBA4A P68366 1/20 0.37
▸ TUBB4B P68371 1/20 0.37
▸ TUBB3 Q13509 1/20 0.37
▸ TUBB2A Q13885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22758039 0.82 FFAR1 (0.53) CD274PDCD1FFAR1FFAR4MAOB
SCHEMBL20540029 0.78 IDO1 (0.42) CA1CA2IDO1AGXTTDP1
SCHEMBL22757791 0.78 CD274 (0.57) CD274PDCD1TDP1MAOB
SCHEMBL21621610 0.77 CD274 (0.59) CD274PDCD1FFAR1
SCHEMBL18320532 0.75 IDO1 (0.55) CA1CA2IDO1AGXTTDP1
SCHEMBL16245269 0.74 PDCD1 (0.76) CD274PDCD1
SCHEMBL29442637 0.73 TDP1 (0.48) CA1CA2IDO1AGXTTDP1
SCHEMBL12951814 0.73 TDP1 (0.48) CA1CA2IDO1AGXTTDP1
SCHEMBL21738369 0.73 CD274 (0.46) CD274PDCD1FFAR1FFAR4ABCB1
Methyl Alcohol SCHEMBL28823289 0.73 IDO1 (0.61) CA1CA2IDO1AGXTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 — — US disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 — — US disclosed
US-20180305315-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2018-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 CD274 1/4885PDCD1 2/4885CA1 2682/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 CD274 1/4885PDCD1 3/4885CA1 2733/4885
US-20180305315-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 CD274 1/4885PDCD1 2/4885CA1 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback